Blackstone Minerals (BSX:AU) has announced Placement of Shortfall and Cleansing Notice
Download the PDF here.
Stem cell research and regenerative medicine are growing markets in the life science sector, and the top stem cell companies are working hard to make advancements that can help patients.
Stem cells serve as an internal repair system in the body. They can divide without limit to replenish other cells as long as the body is still alive. Unsurprisingly, there’s a lot of promise for medical advancements, and there are already stem cell treatments approved by the US Food and Drug Administration (FDA). Still, there is a lot of room for further advancements, and plenty of lab work still needs to be done before stem cell products can be used as cell-based therapies or regenerative medicines.
A report from Grand View Research projects that the global stem cell market will reach US$28.89 billion by 2030. The research firm sees “the rising number of stem cell banks, growing focus on increasing therapeutic potential of these, and extensive research for the development of regenerative medicines” as drivers of this market. The stem cell market and the value of regenerative medicine stocks is expected to grow further via increased government funding for cancer research and the development of cellular therapies to treat various cancers.
Grand View Research reports that in 2024 the pharmaceutical and biotechnology companies segment captured the largest revenue share for the stem cell therapy market at 54.19 percent.
Market cap: US$228.3 billion
First on this list of the top NASDAQ stem cell company stocks is multinational pharma and biotech firm AstraZeneca, which also specializes in other therapeutic areas, including oncology, cardiovascular diseases, the respiratory and central nervous systems and pain control.
While it may be the largest company on this list by market cap, the pharma giant has been slower than its peers in staking a position in the cell therapy market. Its particular focus in oncology is the treatment of solid tumors. The company is also looking at stem cell therapies to treat life-threatening chronic kidney disease and liver disease.
AstraZeneca acquired biotech firm Neogene Therapeutics in 2023, bringing the company’s expertise on T-cell receptor therapies into AstraZeneca’s fold.
Its long-term strategy in this area is to develop ‘off-the-shelf’ allogenic CAR-T therapies to increase the availability and accessibility of the treatments.
Market cap: US$160.05 billion
A global leader in biotech, Amgen is heavily invested in gene-based research and uses advanced human genetics to develop and manufacture therapeutics targeting a variety of diseases with unmet medical needs.
The biotech firm has a multi-year fund agreement with Canada’s Center for Commercialization of Regenerative Medicine (CCRM), which specializes in developing and commercializing regenerative medicine-based technologies and cell and gene therapies. Under the multi-year agreement, both CCRM and Amgen will fund early stage regenerative medicine-based technologies and therapies with research conducted in institutions that are part of CCRM’s global network.
In May 2024, the US FDA approved Amgen’s Imdelltra for the treatment of adult patients with extensive-stage small cell lung cancer, making the drug the first and only T-cell engager therapy available for treating this condition. The therapy activates the patient’s own T cells to attack particular tumor cells.
Market cap: US$137.13 billion
Global biopharmaceutical company Gilead Sciences specializes in developing breakthrough medicines to prevent and treat serious diseases such as HIV, viral hepatitis and cancer.
One of the stem cell therapies in its product portfolio is Yescarta, a CAR-T cell therapy for blood cancer and the first such therapy for certain types of non-Hodgkin’s lymphoma. Yescarta aids a patient’s immune system in fighting the disease. Gilead currently has at least eight cell therapy candidates in its product pipeline, including three in Phase 3 clinical studies targeting high-risk lymphomas and myeloma.
Market cap: US$134.81 billion
French multinational pharmaceutical company Sanofi develops therapeutic products for diabetes and cardiovascular diseases, oncology, immunology, multiple sclerosis, rare diseases, rare blood disorders and vaccines. Its product portfolio includes Mozobil, a hematopoietic stem cell mobilizer that helps bone marrow release stem cells into the bloodstream for transplant into the body.
In 2021, the firm bolstered its regenerative medicine business through the US$1.9 billion acquisition of Kadmon, adding FDA-approved stem cell transplant product Rezurock to its portfolio. Sanofi has since partnered with privately held biotech company Scribe Therapeutics to develop CRISPR-based cell therapies targeting cancers.
The company also has a licensing agreement with Innate Pharma (NASDAQ:IPHA) as the two companies collaborate on developing natural killer cell therapeutics in oncology. One investigational drug candidate under this collaboration is SAR’579, which is in Phase 1/2 studies for the treatment of blood cancers with high unmet needs, including relapsed or refractory acute myeloid leukemia, B cell acute lymphoblastic leukemia and high-risk myelodysplasia. SAR’579 received FDA Fast Track Designation for the treatment of acute myeloid leukemia.
Market cap: US$123.34 billion
Vertex Pharmaceuticals has developed a number of approved treatments for cystic fibrosis, and has a pipeline of genetic and cell therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes.
Vertex and its partner CRISPR Therapeutics (NASDAQ:CRSP) co-developed drug Casgevy, a CRISPR/Cas9 genome-edited cell therapy, received FDA approval in December 2023 for the treatment of sickle cell disease in patients 12 years and older with recurrent vaso-occlusive crises. Casgevy is the first ever treatment based on CRISPR technology to be approved for the US market. In 2024, the drug received validation from the European Medicines Agency and Health Canada for this indication as well.
In addition, Vertex has two active clinical trials for type 1 diabetes cell therapy: X-880, an investigational allogeneic stem cell-derived, insulin-producing islet cell therapy in Phase 1/2/3 clinical trials; and VX-264, designed to be a surgically implanted device in phase 1/2 clinical trials.
Market cap: US$28.67 billion
Immunotherapy company BioNTech is advancing novel therapies for diseases such as cancer. The company combines computational discovery and therapeutic drug platforms to rapidly develop new biopharmaceutical products. The company is best known today for its mRNA vaccine development and in-house manufacturing capabilities, as well as its COVID-19 vaccine, created with partner Pfizer (NYSE:PFE).
BioNTech is engaged in collaborative partnerships aimed at assembling mRNA vaccine candidates for a range of infectious diseases. BioNTech’s portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, CAR-T cell therapies, bispecific checkpoint immuno-modulators, targeted cancer antibodies and small molecules.
The most advanced of its CAR-T product candidates is BNT211, which comprises two drug products designed to induce an immune response against various CLDN6-positive solid tumors, such as ovarian cancer, sarcoma, testicular cancer, endometrial cancer and gastric cancer. BNT211 is in a Phase 1 trial in patients with CLDN6-positive relapsed or refractory advanced solid tumors.
Market cap: US$26.72 billion
Biotechnology company BeiGene specializes in the development of drugs for cancer treatment across a broad range of areas, including esophageal squamous cell carcinoma, non-small cell lung cancer, mantle cell lymphoma, non-Hodgkin’s lymphoma and ovarian cancer. Its clinical development pipeline includes 12 advanced Phase 3 programs.
BeiGene has a strategic partnership with Shoreline Biosciences for the development and commercialization of a genetically engineered natural killer cell therapy.
BeiGene’s bruton tyrosine kinase inhibitor Brukinsa gained FDA approval in early 2023 for patients with chronic lymphocytic leukemia or small lymphocytic leukemia, both forms of non-Hodgkin’s lymphoma.
The company’s monoclonal antibody Tevimbra garnered FDA approval in early 2024 for the treatment of advanced or metastatic esophageal squamous cell carcinoma after prior chemotherapy. Near the end of the year, the European Commission gave the green light to the drug for first-line treatment of advanced/metastatic esophageal squamous cell carcinoma and gastric or gastroesophageal junction cancer, while the FDA approved it for first-line treatment of gastric and gastroesophageal junction cancers in combination with chemotherapy.
Market cap: US$13.1 billion
BioMarin Pharmaceutical develops and commercializes therapies for patients with serious, life-threatening genetic diseases and medical conditions.
The global biotech company focuses on diseases with critical unmet medical needs, as well as products with an opportunity to be first to market or to offer significant benefits over existing products. BioMarin’s portfolio includes eight commercial products and multiple clinical and preclinical product candidates across its therapeutic areas.
Market cap: US$12.98 billion
Biotechnology and pharmaceutical company Moderna is a pioneer in the field of mRNA. The company’s assets include a diverse clinical portfolio of vaccines and therapeutics, plus a large intellectual property portfolio in areas such as mRNA and lipid nanoparticle formulation; it also has an integrated manufacturing plant that allows for both clinical and commercial production.
These assets, along with Moderna’s network of domestic and overseas government and commercial collaborators, allowed for the rapid development of one of the world’s most effective COVID-19 vaccines.
The other therapeutics and vaccines in the company’s pipeline are targeting infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and autoimmune diseases. Moderna has 23 development programs underway across these areas.
Market cap: US$10.3 billion
Bio-Techne develops, manufactures and sells reagents, diagnostic instruments and bioprocessing services for research and clinical applications, including drug discovery. The company’s revenue segments include diagnostics and spatial biology, and protein sciences.
Bio-Techne offers tailored technologies and services for its life science customers developing and producing immune cell, regenerative and gene therapies. The company expanded its Advanced Cell Diagnostics branded RNAscope probe portfolio in February 2025.
‘With over 12,000 citations in clinical and translational research combined, our expanded portfolio of gold-standard RNAscope probes enables customers to accelerate biomarker validation and ultimately improve lives,’ said Dr. Matt McManus, president of Bio-Techne’s diagnostics and spatial biology segment.
Stem cells are the building blocks of life, with special capabilities that are particularly important in both the early and later stages of a human’s lifecycle. Human stem cells have the ability to develop into a variety of different cell types in the body, including organ-specific cells, as well as muscle tissue and bone marrow cells; they can even renew themselves.
Stem cell therapy is the use of stem cells to treat or prevent a disease or condition, including some cancers such as leukemia, lymphoma, multiple myeloma and neuroblastoma. Cell therapy involves the direct administration of cells into the body to promote the body’s natural ability to heal itself.
Stem cell banking is the process of collecting, processing and cryogenically storing potentially life-saving stem cells for future use in therapies and regenerative medicine.
Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.
Jindalee Lithium Limited (Jindalee, the Company; ASX: JLL, OTCQX: JNDAF) advises that the Company has sold its shareholding in Dynamic Metals (ASX: DYM, Dynamic), raising $2.75M before costs.
Dynamic was formerly a Jindalee subsidiary which held Jindalee’s Australian exploration assets. Dynamic was spun out of the Company in January 2023 following a $7M IPO which included a priority entitlement to Jindalee shareholders1, leaving Jindalee as a pure play US lithium company focussed on the 100% owned McDermitt Project (McDermitt), one of the largest lithium deposits in the US and of global significance.
In mid-November 2024 Jindalee announced the results of a Pre-Feasibility Study (PFS) on McDermitt2. The PFS confirmed a 63 year life with the Project producing 1.8Mt Lithium Carbonate at C1 costs of US$8,670/t for the first 40 years and a 5 year payback. The PFS also noted excellent potential to reduce capital and operating costs as well as increase production at McDermitt.
Priority activities following completion of the PFS include engagement with potential funding partners and US Government agencies, together with investigation of opportunities to improve Project economics, permitting and community engagement. The proceeds from the Dynamic sale will enable these activities to be accelerated.
Jindalee’s CEO Ian Rodger commented‘This transaction is firmly aligned with our strategy of advancing McDermitt while preserving shareholder value. At a time when many lithium companies are struggling to raise capital, Jindalee’s ability to unlock funding from a non-core asset enables us to accelerate project development in a less dilutive way. History shows that projects advanced during downturns are best positioned to capture the upswing, and with lithium prices at unsustainable levels, a supply crunch is inevitable. This funding provides us the runway to progress key catalysts—including engagement with potential funding partners and US government agencies, project optimisation, and advancing permitting and community engagement. As one of the most advanced sedimentary lithium projects in the US, McDermitt is strategically positioned to benefit from the policy priorities of the new administration as the US moves to secure domestic supply of critical minerals.’
Click here for the full ASX Release
Craig Hemke of TFMetalsReport.com weighs in on key questions in the gold market, including:
Watch the interview above for more from Hemke on those topics and more.
Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.
Equinox Gold (TSX:EQX,NYSEAMERICAN:EQX) and Calibre Mining (TSX:CXB,OTCQX:CXBMF) have entered into a definitive arrangement agreement to merge, creating a major diversified gold producer in the Americas.
The deal will see Equinox acquire all the outstanding common shares of Calibre in an all-stock transaction, forming a new entity that will continue operating under the Equinox name.
The merger will establish a gold producer with a presence across five countries, anchored by two key Canadian assets: the Greenstone gold mine in Ontario and the Valentine gold mine in Newfoundland and Labrador.
When at full capacity, these mines are expected to produce an average of 590,000 ounces of gold per year.
Overall, Equinox is anticipating production of approximately 950,000 ounces of gold in 2025, with the potential to exceed 1.2 million ounces annually as its cornerstone assets reach full capacity.
Under the terms of the agreement, Calibre shareholders will receive 0.31 Equinox shares for each Calibre share held.
Once the deal is complete, Equinox shareholders will own approximately 65 percent of the new entity, with former Calibre shareholders holding the remaining 35 percent. The new company’s expected market cap is C$7.7 billion.
Equinox CEO Greg Smith called the merger a “transformative step forward” for both companies, stating, “By combining our assets, teams, and financial strength, we are creating a leading Americas-focused gold producer with enhanced scale, resilience, and the ability to generate significant long-term value for our shareholders and stakeholders.”
The new company will also benefit from the expertise of mining industry veterans, including Ross Beaty and Featherstone Capital’s Blayne Johnson and Doug Forster, all of whom will serve on the Equinox board of directors.
The announcement follows Equinox’s record-breaking financial and operational performance in 2024. The company sold 623,579 ounces of gold, generating US$1.5 billion in revenue and US$430 million in operating cashflow.
Results were driven in part by the successful ramp up of production at Greenstone, which achieved commercial production in November 2024 and contributed more than 111,700 ounces of gold in its first partial year of operation.
Additional details on the merger and the new entity’s financial outlook will be provided in Equinox’s upcoming audited consolidated financial statements, which are expected in mid-March.
Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.
Gold royalty companies offer investors exposure to gold and silver with the benefits of diversification, lower risk and a steady income stream.
Royalty companies operating in the resource sector will typically agree to provide funding for the exploration or development of a resource in exchange for a percentage of revenue from the deposit if it begins producing. Similarly, a company with a streaming model may work out an agreement with a resource company for a share of the metal produced from a deposit in exchange for an investment.
These kinds of arrangements benefit both parties. Streamers get access to the underlying commodity at a fixed price and are shielded from cost overruns and spikes in production. Further, if there is a price decrease the metals can be warehoused until the market conditions improve. In both cases, mining companies receive considerable upfront investment during the expensive construction and expansion phases, and unlike loans these investments have longer-term payouts at a fixed amount.
Let’s take a deeper look at how royalties and streaming works, their benefits and the gold and silver royalty and streaming stocks you can invest in.
Gold and silver royalty agreements involve royalty companies agreeing to provide funding for the exploration or development of a precious metals resource in exchange for a percentage of revenue from the deposit if it begins producing metals.
The foundation for royalties dates back a few hundred years. Originally, they were payments made to the British monarchy in exchange for miners’ rights to operate gold and silver mining operations on lands held by the crown. Today, these arrangements still exist, with mining operators paying the government a share of the revenues generated from exploiting resources on public lands.
The first royalty paid to a company in the gold sector was an agreement in 1986 in which Franco-Nevada (TSX:FNV,NYSE:FNV) made a US$2 million investment into Western States Minerals’ Goldstrike small heap-leach mine in Nevada, US, for a 4 percent share of revenues collected from the mine. Western States was sold the same year to Barrick Gold (TSX:ABX,NYSE:GOLD). Barrick discovered a far larger resource at the site and the royalty has since earned Franco-Nevada more than US$1 billion.
This early example set a precedent for the industry. It saw Franco-Nevada, which was then a gold exploration company, lock itself into what became one of the largest gold mineral resources in the world at a relatively low overhead while avoiding future costs associated with the growth and maintenance of the mine.
Gold and silver streams work in a similar manner to the royalty model but returns are in the form of physical metals rather than funds. In return for investing in an asset, a gold streaming company may work out an agreement with a resource company for a share of the metal produced from a deposit, or for the ability to purchase the metal at a lower price than market value.
This is also a popular model with base metal mining companies whose operations result in gold and/or silver by-products. In these cases, gold and silver streaming companies may work out a deal with a base metal mining operation to take delivery of a certain amount of precious metals at an agreed upon price.
The Goldstrike royalty made Franco-Nevada what it is today, but its largest contributing asset in its portfolio is a deal with Lundin Mining (TSX:LUN,OTC Pink:LUNMF) for a stream of the gold and silver resources extracted from its Candelaria copper mine in Chile.
Under the terms of the deal, which was part of Lundin’s 2014 acquisition of Freeport-McMoRan’s (NYSE:FCX) stake in Candelaria, Franco-Nevada provided a US$648 million deposit in exchange for a 68 percent stream of the asset’s silver and gold. This will lower to 40 percent once 720,000 ounces of gold and 12 million ounces of silver have been delivered, which the company currently predicts will take place in 2027.
While Franco-Nevada does have to pay for the metal, the agreed upon amount is far under the current market value. At the time, the deal was set at US$400 for each ounce of gold and US$4 per ounce of silver with a 1 percent inflationary adjustment, or market price if that was less.
Royalty and streaming companies are largely seen as a lower-risk investment than mining companies. Lower operational costs and higher portfolio diversification means they are hedged against a mine shutdown, natural disaster, market forces or the politics that may affect the nature of an operation or project. However, that’s not to say royalty and streaming deals aren’t without their risks.
In many ways, gold royalty companies are like venture capitalists in the tech industry, working to fund many projects in the hopes that some will see big payoffs that offset the loss from the ones that don’t make it. This means they need large access to funding in order to build their portfolios.
To get funding, royalty and streaming companies have several options: using cash on hand, raising debt through loans or issuing more shares. Each of these options carries risk. Using cash to pay for investments could reduce the size of the safety net and eat into company liquidity, debt needs to be managed to ensure that payments don’t exceed income and the issuance of stock could lead to an overall devaluation of share price and impact investor sentiment.
Once companies have developed strong cash flows and good liquidity, they are able to take advantage of their own reserves, without the need to worry about loans or stock dilution. The same cannot be said for the up-and-coming companies who need to rely on external funding to make deals, making them riskier.
These companies provide a good entry point for investors with lower share price, and have more potential to return higher percentage gains in share price, they also bear more risk. With more reliance on raising external capital, there is a greater need for deals to be successful and a greater chance for a company to incur more debt load or stock dilution.
Diverse portfolios can help reduce the risk associated with a royalty company, and companies like Franco-Nevada have the industry knowledge and financial capital to take some risks. As of February 2025, the company has 432 assets on their books; 117 are producing, 38 are in the advanced stages of development. It’s the 277 more that are in the exploration phase that represents the greatest risk, many of which will never provide returns.
Of course, unforeseen events can affect both mining and royalty companies alike, particularly when assets that take up a larger percentage or a portfolio are affected. Franco-Nevada had more than US$1 billion invested in First Quantum’s (TSX:FM,OTC Pink:FQVLF) Cobre Panama mine before it was shuttered by the Panamanian government following protests at the end of 2023. The mine brought in US$223.3 million for Franco-Nevada in 2022 and represented nearly a quarter of its precious metal income. While it fared better than First Quantum, the royalty company’s share price took a significant hit.
The biggest companies in the precious metals royalty and streaming space have long histories and have built positive reputations on the backs of strong investments. They offer a means for investors to de-risk an entry into the gold sector by maintaining an arms-length attachment to it.
The five gold and silver royalty and streaming companies on this list had market caps above $1 billion in their respective currencies as of February 19, 2025.
Market cap: C$44.46 billion
Wheaton Precious Metals was established in 2004 as Silver Wheaton with a focus on silver streaming. Goldcorp held a majority interest, but began to reduce it in 2006 and by 2008 had completely divested itself. By that time, Silver Wheaton had begun to diversify into other precious metals. The following year, Silver Wheaton acquired rival silver streaming stock Silverstone Resources in a C$190 million deal.
Silver Wheaton changed its name in 2017 to Wheaton Precious Metals and has since built itself into one of the largest players in the gold and silver royalty and streaming space, with investments in 13 operating mines and 26 development projects across four continents.
Market cap: C$38.23 billion
A trailblazer in the gold royalty business, Franco-Nevada has set a high bar. The current iteration of the company was spun out of Newmont (TSX:NGT,NYSE:NEM) in what became a C$1.1 billion initial public offering, one of the biggest IPOs of 2007.
Franco-Nevada now has a portfolio of more than 100 producing assets around the world with investments in gold, silver, base metal and oil and gas operations, which generate more than US$1.2 billion for the company annually. See the sections above for more information on Franco-Nevada’s royalty and streaming deals.
Market cap: US$9.82 billion
Royal Gold got its start in 1981 as oil and gas exploration and production company Royal Resources Corporation. Responding to shifts in the overall resource market, by 1987, Royal Gold was born with a focus on building a portfolio of minority positions in significant gold properties operated by major mining firms.
Today, Royal Gold is a leading precious metals streaming and royalty company with interest in 175 properties, of which 42 are producing assets, across 17 countries. One of the most significant principal assets for this gold royalty stock is the Cortez gold mine in Nevada owned by Barrick and Newmont.
Market cap: C$5.1 billion
Osisko Gold Royalties was created in 2014 as a spinoff deal between Osisko Mining (TSX:OSK), Yamana Gold and Agnico Eagle Mines (TSX:AEM,NYSE:AEM). The deal was made in an attempt to prevent a hostile takeover of Osisko Mining and its Canadian Malartic gold complex by Goldcorp.
In the deal, Osisko Gold Royalties carried with it a 5 percent net smelter return royalty from the Canadian Malartic mine. Now owned by Agnico Eagle, the complex in Québec remains a cornerstone of Osisko’s business today.
The gold and silver royalty and streaming company has gone on to acquire 185 assets, 23 of which are producing, across 6 continents with a majority in North America.
Market cap: C$2.5 billion
Sandstorm Gold Royalties was founded in 2008 as a small-startup and has since become a multi-billion dollar gold and silver royalty and streaming company. Its producing assets include Pan American Silver’s (NYSE:PAAS,TSX:PAAS) Ceo Moro gold-silver mine, and Cerrado Gold’s (TSX:CERT,OTCQX:CRDOF) Las Calandrias gold-silver mine, both in Argentina.
Sandstorm’s royalty portfolio boasts more than 230 assets, of which 41 are producing assets, located across more than a dozen countries.
There are also small-cap gold and silver royalty and streaming companies you can invest in and offer a lower-cost option for investors who are comfortable with a little more risk. Like their larger counterparts, small-cap gold royalty stocks offer a lower-risk investment than getting into a small-cap mining company but still provide access to the underlying precious metals market.
The five small-cap gold and silver royalty companies on this list had market caps above $10 million in their respective currencies as of February 19, 2025.
Market cap: C$408.08 million
Metalla Royalty & Streaming focuses on gold, silver and copper projects. The company’s royalty model involves acquiring royalties and streams by offering resource companies Metalla shares and cash.
The mid-tier royalty and streaming company’s asset portfolio includes more than 100 projects across North America, South America and Australia. Its cornerstone assets include IAMGOLD (TSX:IMG,NYSE:IAG) and Sumitomo Metal Mining’s (TSE:5713) Côté gold mine in Ontario, Canada.
Market cap: US$242.12 million
Gold Royalty is building a diversified portfolio of more than 200 gold royalty and gold streaming interests based on net smelter return royalties on properties in the Americas.
The company’s revenue generating investments includes one of the most well-known gold-producing mines in the world, Agnico Eagle’s Canadian Malartic complex in Québec.
Market cap: C$112.44 million
Founded in 2014, Sailfish Royalty’s asset portfolio is much smaller than the other gold royalty stocks on this list. It consists of one producing mine as well as two development-stage and two exploration-stage properties in the Americas.
In Nicaragua, Sailfish has a gold stream equivalent to a 3 percent net smelter return on Mako Mining’s (TSXV:MKO,OTCQX:MAKOF) San Albino gold mine and a 2 percent net smelter return on the area surrounding the mine. The company also holds a 13,500 ounce per month silver stream at the property, which will run until May 2025 with the option to extend.
Market cap: C$41.96 million
Empress Royalty’s business model involves investing in mining companies in various stages of exploration through production who need further non-dilutive capital to fund their projects and operations.
Empress’ gold and silver royalty and streaming portfolio includes four producing assets, with two in the Americas and two in Africa: the privately owned Sierra Antapite gold mine in Peru, Luca Mining’s (TSXV:LUCA,OTCQX:LUCMF) Tahuehueto silver mine in Mexico, the privately owned Manica gold project in Mozambique and Golconda Gold’s (TSXV:GG,OTCQB:GGGOF) Galaxy gold mine in South Africa.
Market cap: C$16.1 million
Silver Crown Royalties is a revenue-generating silver-only royalty company focusing on silver as by-product credits. The company targets royalty originations on producing or near-producing assets in tier 1 jurisdictions.
Silver Crown has two producing assets in its portfolio: Gold Mountain Mining’s (TSX:GMTN) Elk gold project in British Columbia, Canada, and private Canadian company Pilar Gold’s PGDM mine in Brazil.
Those who want more broad exposure to the precious metals markets may want to buy shares of an exchange-traded fund that includes gold and silver royalty and streaming stocks. Here are a few to get you started.
Betashares Global Royalties ETF (ASX:ROYL)
Betashares Global Royalties ETF is an Australian ETF that tracks the performance of an index of global companies that earn a significant amount of their revenue from royalty income, royalty-related income and intellectual property income. The fund’s top holdings include Wheaton Precious Metals, Franco-Nevada and Royal Gold.
Betashares Global Gold Miners ETF (ASX:MNRS)
Betashares Global Gold Miners ETF tracks the performance of an index of the world’s largest gold mining companies outside of Australia, hedged into Australian dollars. Wheaton Precious Metals, Franco-Nevada and Royal Gold are also among the fund’s top holdings.
VanEck Gold Miners ETF (ARCA:GDX)
VanEck Gold Miners ETF is a US gold ETF that aims to replicate the performance of the NYSE Arca Gold Miners Index by holding large-cap gold mining stocks and precious metals royalty companies. As with the other gold ETFs on this list, its top holdings include Wheaton Precious Metals, Franco-Nevada and Royal Gold.
Securities Disclosure: I, Dean Belder, hold no direct investment interest in any company mentioned in this article.
Tungsten’s importance in a wide range of industrial categories, from smartphones to car batteries, means demand is likely to rise. At the same time, supply chain disruptions and increased production costs are weighing on global supply, making it important to learn about the top global tungsten producers.
Tungsten has many applications. It’s used in electrical wires, as well as in welding, heavy metal alloys, turbine blades and as a lead substitute in bullets. The metal can also be found in heating and electrical contacts.
Tungsten prices have traded upward in recent years, and the industry’s supply and demand dynamics are expected to push the metal higher in 2025 and beyond. Total revenue for the tungsten market is expected to grow at a compound annual growth rate of 8 percent through 2024 to 2032 to reach nearly US$9.49 billion in value.
With that in mind, it’s worth being aware of which countries produce the most tungsten. According to the US Geological Survey, global tungsten production came in at 81,000 metric tons (MT) in 2024, up slightly from 2023’s 79,500 MT. The vast majority of tungsten mining and processing occurs in China. Looking forward to 2025, increased production is seen coming from mines in South Korea and Australia.
Here’s an overview of tungsten production by country in 2024, as per data from the US Geological Survey.
Tungsten production: 67,000 metric tons
Tungsten reserves: 2.4 million metric tons
In 2024, China produced 67,000 metric tons of tungsten, up by 1,000 MT from 2023. The country is the world’s largest producer of the metal by a wide margin, accounting for more than 80 percent of total annual tungsten output worldwide.
That said, China’s tungsten production has been falling in recent years — the Asian nation has limited the quantity of tungsten-mining and export licenses it awards and has imposed quotas on tungsten concentrate production. The country has also recently increased environmental inspections.
China has been the main source of tungsten imported into the US since 2017, and the country accounted for 27 percent of US tungsten imports in 2024.
In response to US President Donald Trump’s imposition of 10 percent tariffs on imports from China in February 2025, the Government of China immediately announced strict export controls on tungsten and four other key metals used in several important industries, including defense. Tighter tungsten supply out of China may lead to higher prices for the metal despite growing production from ex-China sources.
Tungsten production: 3,400 metric tons
Tungsten reserves: 140,000 metric tons
Vietnam’s tungsten production in 2024 came to 3,400 metric tons, down by 100 MT from the previous year. Privately owned Masan Resources runs the Vietnam-based Nui Phao mine, which it says is the largest tungsten-producing mine outside China. It is also one of the lowest-cost producers of tungsten in the world.
In 2024, Vietnam accounted for 8 percent of US tungsten imports.
Tungsten production: 2,000 metric tons
Tungsten reserves: 400,000 metric tons
Russia produced 2,000 metric tons of tungsten in 2024, on par with the last few years. The war between Russia and Ukraine has hampered Russia’s ability to trade and make deliveries of tungsten to the world market as it continues to face sanctions. The Tyrnyauz tungsten-molybdenum mine is the largest tungsten deposit in the country and one of the largest globally.
Russia is a significant supplier of the metal to Europe, but restrictions have increased the continent’s dependency on Chinese imports. At the same time, the war is fueling tungsten demand given the metal’s use in ammunitions.
Tungsten production: 1,700 metric tons
Tungsten reserves: 29,000 metric tons
In 2024, North Korea produced 1,700 metric tons of tungsten production, up by 100 MT over the previous year. The Mannyŏn mine in North Hwanghae province is the country’s largest tungsten mine. Its name means 10,000 years in reference to its vast reserves.
Tungsten ore is North Korea’s third highest export by value, worth nearly US$26 million in 2023, with the majority being consumed by China. Tungsten’s high spot in North Korea’s export market may be due to the fact that it’s one of the few metals not listed under UN sanctions on the country’s trade.
Tungsten production: 1,600 metric tons
Tungsten reserves: Not available
Bolivia’s tungsten production in 2024 was 1,600 metric tons, a gain of 100 MT over the previous year. The South American country has increased its tungsten production since 2014 as a result of moves to promote its tungsten industry. Bolivia accounted for 8 percent of US tungsten imports in 2024.
The Bolivian mining industry is heavily influenced by Comibol, a state-owned mining umbrella company.
Tungsten production: 1,200 metric tons
Tungsten reserves: Not available
Rwanda produced 1,200 metric tons of tungsten in 2024, on par with 2023’s output. Tungsten is one of the most common conflict minerals in the world, meaning that at least some of it is produced in war zones and is sold to perpetuate fighting.
While Rwanda has promoted itself as a source of conflict-free minerals, concerns remain about its tungsten output. Nevertheless, it is an important exporter of tungsten, accounting for 31 percent of global tungsten trade in 2022.
One of the largest tungsten producers in Rwanda is privately owned Trilogy Metals, which owns the Nyakabingo tungsten ore mine. Trilogy’s largest shareholder is UK-based private industrial company Techmet, which is working to secure a viable technology metal supply chain.
Tungsten production: 1,000 metric tons
Tungsten reserves: 570,000 metric tons*
In 2024, Australia produced 1,000 metric tons of tungsten. This represents a more than 130 percent jump in output from 2023 levels, taking it from the ninth spot on the previous year’s list to rank seventh in global tungsten production for 2024.
There are several operating tungsten mines in Australia. EQ Resources (ASX:EQR) is an Australian tungsten miner producing the metal at its Mount Carbine asset in North Queensland. On the island state of Tasmania, Group 6 Metals (ASX:G6M) brought the historic Dolphin tungsten mine back into production in 2023. The island also contains private firm Tasmania Mines’ Kara tungsten mine
Tungsten projects under development in Australia include the Molyhil tungsten-molybdenum-copper project located in the Northern Territory. Molyhil is a 75/25 joint venture between Thor Energy (LSE:THR,OTC Pink:THORF) and Investigator Resources (ASX:IVR). According to Mining Database Online (MDO), Investigator is working toward completing a scoping study on Molyhil, based on an updated May 2024 mineral resource estimate, in the first half of 2025.
Another company with Australia-based tungsten projects is Tungsten Mining (ASX:TGN), whose properties include Mount Mulgine, Big Hill and Kilba in Western Australia, as well as Watershed in Northeast Queensland and Hatches Creek in the Northern Territory.
* Joint Ore Reserves Committee-compliant or equivalent reserves were 220,000 metric tons.
Tungsten production: 800 metric tons
Tungsten reserves: 10,000 metric tons
Austria’s tungsten production in 2024 was 800 metric tons, down 50 MT from the previous year. Much of that production can be attributed to Wolfram’s Mittersill mine, which is located in Salzburg and hosts Europe’s largest tungsten deposit.
Tungsten production: 700 metric tons
Tungsten reserves: 66,000 metric tons
Spain produced 700 metric tons of tungsten in 2024, up 50 MT over the previous year.
There are a number of companies engaged in the exploration, development and mining of tungsten assets in Spain. Australia’s EQ Resources, which acquired tungsten producer Saloro in 2023, now controls the Barruecopardo Mining and Processing operation. MDO reports that a program is underway to upgrade the plant and improve recoveries with completion expected by the end of 2025.
As for Spanish tungsten assets under development, Almonty Industries (TSX:AII,OTCQX:ALMTF) owns the permitting-phase Valtreixal tungsten-tin project.
Tungsten production: 500 metric tons
Tungsten reserves: 3,400 metric tons
In 2024, Portugal produced 500 metric tons in 2024, up by 50 MT from that produced in the previous year.
The European country has the lowest-known tungsten reserves figure out of all the nations on this list, totaling just 3,400 MT. Almonty Industries’ Panasqueira mine is Portugal’s largest tungsten-producing operation. ‘The Panasqueira Mine has some of the highest tungsten recovery rates in the industry, consistently averaging 80 (percent),’ MDO states.
Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.
Trigg Minerals Limited (ASX: TMG| OTCQB: TMGLF) (‘Trigg’ or the ‘Company’) has announced Unlocking a New High-Grade Antimony-Tungsten Structure Adds Potential to Wild Cattle Creek.
HIGHLIGHTS
The recent Chinese government suspension of tungsten exports, effective February 2025, has sent shockwaves through global markets. China is the world’s dominant supplier, responsible for over 80% of global tungsten production, making this a pivotal moment for alternative sources to emerge.
Trigg Minerals’ (ASX: TMG) Wild Cattle Creek deposit at its 100% owned Achilles Project is now in sharp focus. Previously overlooked in historical drilling, the high-grade tungsten mineralisation could be crucial in securing a domestic supply of this critical mineral.
Wild Cattle Creek has long been known for its high-grade antimony, with Trigg recently upgrading the Mineral Resource Estimate (MRE) to 1.52Mt at 1.G7% Sb, containing 2G,G02 tonnes of antimony comprising 0.G6Mt at 2.02% Sb (Indicated) and 0.56Mt at 1.88% Sb (Inferred); see ASX announcement dated 19 December 2024. However, tungsten mineralisation—strongly associated with the alteration selvage near high-grade antimony zones—has largely been overlooked.
Trigg has confirmed that high-grade antimony and tungsten (Figure 1; Table 1) are also present in a subparallel vein lying approximately 35m beneath (i.e. north of) the primary Wild Cattle Creek system. This vein extends over 100 metres in the westernmost sections of the deposit. It remains open at depth and along strike, highlighting the strong potential for additional resources in antimony and tungsten.
Click here for the full ASX Release